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Abstract
Epithelial  ovarian  cancer  (EOC)  accounts  for  the  most  gynecologic  malignancy-associated
deaths  in  the  United  States.  Enhancer  of  zeste  homolog  2  (EZH2),  which  silences  gene
expression through generating trimethylation on lysine 27 residue of histone H3 (H3K27Me3), is
often overexpressed in EOCs and has been suggested as a therapeutic target. However, the
mechanism underlying EZH2 overexpression in EOCs is unknown. Here, we show that EZH2 is
upregulated at the transcription level, and two CCAAT boxes in the proximal regions of the
human EZH2gene promoter  are  critical  for  its  transcription  inEOCcells.  Indeed,  NF-YA,  the
regulatory subunit of the CCAAT-binding transcription factor NF-Y, is expressed at higher levels
in human EOCs than in primary human ovarian surface epithelial (HOSE) cells. In addition, there
is a positive correlation between expression of NF-YA and EZH2 in EOCs. Notably, high NF-YA
expression predicts shorter overall survival in patients with EOCs. The association of NF-YA with
the promoter of the human EZH2 gene is enhanced in human EOC cells compared with primary
HOSE  cells.  Significantly,  knockdown  of  NF-YA  downregulates  EZH2,  decreases  H3K27Me3
levels, and suppresses the growth of human EOC cells both in vitro and in a xenograft mouse
model. Notably, NF-YA knockdown induces apoptosis ofEOCcells and ectopic EZH2 expression
partially rescues apoptosis induced by NF-YA knockdown. Together, these data reveal that NF-Y
is  a  key  regulator  of  EZH2  expression  and  is  required  for  EOC  cell  proliferation,  thus
representing a novel target for developing EOC therapeutics. © 2013 American Association for
Cancer Research.
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